European Journal of Haematology

Article	Citations
Issue Information	77
	47
	45
Clinical efficacy of simoctocog alfa versus extended half‐life recombinant FVIII concentrates in hemophilia A patients undergoing personalized prophylaxis using a matching‐adjusted indirect	37
Post‐transplant maintenance therapy in patients with FLT3‐mutated acute myeloid leukemia: Real‐world treatment patterns and outcomes	34
Enhancing thalassemia gene carrier identification in non‐anemic populations using artificial intelligence erythrocyte morphology analysis and machine learning	33
Issue Information	29
Issue Information	27
Long‐term effectiveness of eculizumab: Data from the International PNH Registry	25
The association of age and adverse events of PEG‐asparaginase in a pediatric tertiary care hospital; a retrospective review	25
Effects of tertiary palliative care on the pattern of end‐of‐life care in patients with hematologic malignancies in Korea	23
Platelet transfusions and predictors of bleeding in patients with myelodysplastic syndromes	22
Plasma microbial cell‐free DNA following chimeric antigen receptor T cell therapy in pediatric patients with relapsed/refractory leukemia	22
Desensitization protocol to lenalidomide: An effective and safe treatment modality for delayed hypersensitivity‐induced rash in patients with multiple myeloma	22
Nationwide study of eculizumab in paroxysmal nocturnal hemoglobinuria: Evaluation of treatment indications and outcomes	21
Flow cytometry for comprehensive assessment of platelet functional activity in response to ADP stimulation	19
Application of thromboelastography to predict the severity of bleeding after chimeric antigen receptor (CAR)‐T cell therapy in patients with hematological malignancy	19
Pixantrone as a bridge to CAR‐T treatment in high‐grade transformation of follicular lymphoma	18
Augmenter of liver regeneration promotes drug resistance of acute lymphoblastic leukemia through the alteration of mitochondrial functions and the inhibition of the mitochondrial apoptosis pathway	17
Prophylaxis with recombinant von Willebrand factor in patients with type 3 von Willebrand disease: Results of a post hoc analysis from a phase 3 trial	17
Impact of Gut Microbiota and Inflammatory Cytokines on Immune Thrombocytopenia	17
Individualized busulfan dosing improves outcomes compared to fixed‐dose administration in pre‐transplant minimal residual disease‐positive acute myeloid leukemia patients with intermediate‐risk underg	17
Myeloproliferative Neoplasms and Dementia Risk: A Population‐Based Cohort Study	17
Vaccination in Multiple Myeloma: Challenges and Strategies	16
Efficacy and Safety of Bendamustine‐Rituximab for Nodular Lymphocyte Predominant Hodgkin Lymphoma	16

Utilization and outcome disparities in allogeneic hematopoietic stem cell transplant in the United States	16
Comparison of Hetrombopag and Eltrombopag Added to First‐Line Immunosuppressive Therapy in Severe Aplastic Anemia	16
Ruxolitinib in patients with polycythemia vera resistant and/or intolerant to hydroxyurea: European observational study	15
BAY 81‐8973 Demonstrates Long‐Term Safety and Efficacy in Children With Severe Haemophilia A: Results From the LEOPOLD Kids Extension Study	15
Relationship between hemoglobin, hemolysis, and transcranial Doppler velocities in children with sickle cell disease: Results from a long‐term natural history study in Italy in the era of multimodal t	15
	15
Issue Information	15
Health‐related quality of life in patients with β‐thalassemia: Data from the phase 3 BELIEVE trial of luspatercept	14
Prognostic impact of translocation t(11;14) and of other cytogenetic abnormalities in patients with AL amyloidosis in the era of contemporary therapies	14
A low‐dose rituximab regimen for first‐line treatment of acquired haemophilia A	14
Are we ready for personalizedCAR‐Ttherapy?	14
Transfusion requirements and complication rate in β‐thalassemia intermedia due to heterozygous β‐globin gene mutation and triplicated α‐globin genes	13
Soluble MIC‐A, IPI, and response to treatment strongly predict survival in patients with germinal center diffuse large B cell lymphoma	13
Efficacy of COVID‐19 vaccination in adult patients with sickle cell disease during the Omicron wave in France	13
Venous thromboembolism prophylaxis in hospitalized sickle cell disease and sickle cell trait patients	13
The Amyloidosis Intersection: Dual Amyloid Types in a Single Host	12
Intracranial hemorrhage in newly diagnosed non‐promyelocytic acute myeloid leukemia patients admitted for intensive induction chemotherapy	12
HyperCVAD versus pegaspargase‐containing regimens for Hispanic adults with newly diagnosed B‐cell acute lymphoblastic leukemia	12
Isatuximab, Carfilzomib, and Dexamethasone Combined With Late Autologous Stem Cell Transplantation: A Synergistic Strategy for First Relapse Multiple Myeloma	12
Momelotinib Is Effective in Treatment for VEXAS Syndrome: Two Cases Within the AGMT Austrian Myeloid Registry	12
Antiemetic prophylaxis regimens in haematologic malignancies patients undergoing a hematopoietic stem cell transplantation. Which is the best standard of care? A systematic review	11
Hematological and genetic profiles of persons with co‐inherited heterozygous β‐thalassemia and supernumerary α‐globin genes	11
Outcomes of COVID‐19 hospitalizations in patients with sickle cell disease: A nationwide analysis	11
Pharmacokinetics and pharmacodynamics of an oral formulation of decitabine and tetrahydrouridine	11
Construction of Lymphoma Organoids and Applications in Tumor Microenvironment Research	11
Persistent decreased bone marrow CD3+CD56+ T lymphocytes are inversely associated with mature granulocytes in myelodysplastic syndromes	11
Mutational profile, outcomes, and impact of allogeneic hematopoietic stem cell transplantation in adult patients with acute myeloid leukemia and inconclusive cytogenetic analysis	11
Home‐Based Daratumumab in Patients With Multiple Myeloma	11
	11
Sequencing and combination of currentsmall‐moleculeinhibitors for chronic lymphocytic leukemia: Where is the evidence?	11
BCR::ABL1 kinase domain mutation testing and clinical outcome in a nationwide chronic myeloid leukemia patient population	11
Estrogen‐based hormonal therapy and the risk of thrombosis in COVID‐19 patients	10
Secondary Malignancies After Autologous Stem Cell Transplantations in Patients With Malignant Lymphoma and Multiple Myeloma	10
Intensive salvage chemotherapy with VDTPACE or mCBAD followed by hematopoietic stem‐cell support for refractory/relapsed multiple myeloma	10
Assessment of joint bleeding and target joints in patients with severe or moderately severe hemophilia B (factor IX ≤2%) receiving prophylaxis with rIX‐FP in the PROLONG‐9FP clinical trial program	9
Three cases of late‐onset post CAR‐T therapy isolated CNS relapse in R/R large B‐cell lymphoma	9
Clinicopathological Prognostic Model for Survival in Adult Patients With Secondary Hemophagocytic Lymphohistiocytosis	9
	9
Issue Information	9
End of treatment FDG‐PET in primary mediastinal B‐cell lymphoma treated with R‐chemotherapy: Prognostic indicator and implications for consolidation radiotherapy	9
Long‐term remission in a patient with relapsed Richter's transformation treated with CD19‐directed chimeric antigen‐receptor T‐cells after allogeneic stem cell transplantation	9
Impact of Conditioning Intensity on Survival in Adult Patients (< 65 Years) With Acute Myeloid Leukemia Receiving Antithymocyte Globulin and Post‐Transplantation Cyclophosphamide Based GVHD	9
Impact of prior treatment on selinexor, bortezomib, dexamethasone outcomes in patients with relapsed/refractory multiple myeloma: Extended follow‐up subgroup analysis of the BOSTON trial	9
Use of midostaurin in mixed phenotype acute leukemia with FLT3 mutation: A case series	9
A post hoc analysis of PROTECT VIII Kids assessing long‐term efficacy and safety of damoctocog alfa pegol in adolescents with severe haemophilia A	9
Repeated immunosuppressive rabbit antithymocyte globulin therapy for adult patients with relapsed or refractory aplastic anemia	9
Adherence and Quality of Life in Adult Patients With Haemophilia A, Haemophilia B and Von Willebrand Disease: A National Cross‐Sectional Survey	9
Relationships between T‐lymphocytes and physical function in adults with chronic lymphocytic leukemia: Results from the HEALTH4CLL pilot study	9
Impact of newly diagnosed extramedullary myeloma on outcome after first autograft followed by maintenance: A CMWP‐EBMT study	9
Retracted: Bevacizumab synergises with the BCL 2 inhibitor venetoclax to effectively treat B‐cell non‐Hodgkin's lymphoma	9

Issue Information	9
Platelet kinetics in patients with chronic immune thrombocytopaenia treated with thrombopoietin receptor agonists	9
The incidence, complications, and treatment of iron deficiency in pregnancy	9
	8
Asciminib in Advanced‐Line Treatment of Chronic Myeloid Leukemia	8
	8
A precision‐based exercise program for patients with multiple myeloma	8
Survival and risk of vascular complications in myelofibrosis—A population‐based study from the Swedish MPN group	8
Long‐term haematological response and maintained immunological function after laparoscopic subtotal splenectomy in patients with hereditary spherocytosis	8
Subclones with variants of uncertain clinical significance might contribute to ineffective hemopoiesis and leukemia predisposition	8
Global prevalence of anemia among women of reproductive age, 2000–2019	8
15‐color highly sensitive flow cytometry assay for post anti‐CD19 targeted therapy (anti‐CD19‐CAR‐T and blinatumomab) measurable residual disease assessment in B‐lymphoblastic le	8
Anti‐thymocyte Globulin and Post‐Transplant Cyclophosphamide do not abrogate the inferior outcome risk conferred by human leukocyte antigen‐A and ‐B mismatched donors	8
	8
Autologous stem cell transplantation in multiple myeloma patients over 70 years: A GIMEMA Lazio Working Group experience in a retrospective case–control study	8
	8
	8
Impact of infectious comorbidity and overall time of hospitalization in total outpatient management of acute myeloid leukemia patients following venetoclax and hypomethylating agents	8
Chimeric antigen receptor T cells for acute myeloid leukemia	7
Comparison of outcomes between Hodgkin's lymphoma patients treated in and outside clinical trials: A study based on theEORTC‐Dutchlate effects cohort‐linked data	7
Healthcare resource utilization in patients with myeloproliferative neoplasms: A Danish nationwide matched cohort study	7
Pathogenic Mechanisms of Systemic Mastocytosis: Unraveling the Genetic Complexity, Bone Marrow Microenvironment, and Clinical Challenges	7
Fetal Hemoglobin Decrease During Voxelotor Treatment	7
Long‐term outcome in patients with follicular lymphoma following high‐dose therapy and autologous stem cell transplantation	7
Relevance, Risks, and Benefits of Early‐Phases Clinical Trials Participations for Patients With Hematological Malignancies From 2008 to 2023	7
Outpatient consolidation chemotherapy with intermediate dose cytarabine has similar survival and relapses rates in acute myeloid leukemia as compared to high dose cytarabine: A single center analysis	7
JAK2V617F drives gut microbiota differences in patients with myeloproliferative neoplasms	7
Droplet digital PCR for sensitive relapse detection in acute myeloid leukaemia patients transplanted by reduced intensity conditioning	7
Phenotype of BTK‐lacking myeloid cells during prolonged COVID‐19 and upon convalescent plasma	7
Interferon gamma regulates a complex pro‐survival signal network in chronic lymphocytic leukemia	7
Hematopoietic cell transplantation for telomere biology diseases: A retrospective single‐center cohort study	7
Re‐evaluation of rituximab therapy for idiopathic Castleman disease: Retrospective study from single‐center experience	7
Cardiovascular risk in chronic myeloid leukaemia: A multidisciplinary consensus on screening and management	7
Musculoskeletal Symptoms and Misdiagnoses in Children With Acute Myeloid Leukaemia: A Nationwide Cohort Study	7
Implementation of International Prognostic Index with flow cytometry immunophenotyping for better risk stratification of chronic lymphocytic leukemia	7
Bone marrow expression of CD68/CD163 macrophages, IL‐17 and FOXP3 cells in aplastic anemia and their relation to prognosis	7
Development and validation of the sickle cell stress scale‐adult	7
ProGraME: A novel flow cytometry algorithm for the diagnosis of low‐risk myelodysplastic syndromes in patients with cytopenia	7
Risk factors for hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation in a letermovir‐exposed CMV‐free population receiving PTCy	7
Health economic evidence for the use of molecular biomarker tests in hematological malignancies: A systematic review	7
Clinical outcomes of patients referred for asymptomatic neutropenia: A focus on racial disparities in hematology	7
The applicability of the central line‐associated bloodstream infection (CLABSI) criteria for the evaluation of bacteremia episodes in pediatric oncology patients	7
Exercise in newly diagnosed patients with multiple myeloma: A randomized controlled trial of effects on physical function, physical activity, lean body mass, bone mineral density, pain, and quality of	7
Trends and in‐hospital cardiac complications in patients with atrial fibrillation undergoing allogeneic stem cell transplant: A National Inpatient Sample analysis (2002–2019)	7
Screening for multidrug‐resistant organisms in high‐risk hospitalized patients with hematologic diseases	7
	6
The current challenges faced by people with hemophilia B	6
Real‐world utility of early measurable residual disease assessments by multi‐parametric flow cytometry in adult patients with B‐lymphoblastic leukemia receiving Hyper‐CVAD induction chemoth	6
Effectiveness of progressive moderate‐vigorous intensity elastic resistance training on quality of life and perceived functional abilities in people with hemophilia: Secondary analysis of a randomized	6
Issue Information	6
Outcomes in Kaposi's sarcoma‐associated herpesvirus ‐associated primary effusion lymphoma and multicentric Castleman's disease in patients with human immunodeficiency virus (	6
Intravenous anakinra for the treatment of haemophagocytic lymphohistiocytosis/macrophage activation syndrome: A systematic review	6
	6
Infection epidemiology in relation to different therapy phases in patients with haematological malignancies receiving CAR T‐cell therapy	6
Progressive multifocal leukoencephalopathy in the context of newer therapies in hematology and review of new treatment strategies	6
Insulin‐like growth factor‐1 and insulin‐like growth factor binding protein‐3: impact on early haematopoietic reconstitution following allogeneic haematopoietic stem cell transplantation	6
Conditioning with melphalan 200 mg/m2 and subsequent ASCT improves progression‐free and overall survival in elderly myeloma patients compared to standard of care	6
	6
The net clinical benefit of targeted agents in the upfront treatment of elderly/unfit chronic lymphocytic leukemia patients: Results of network meta‐analysis	6
Efficacy of conventional‐dose cytarabine, idarubicin and thioguanine versus intermediate‐dose cytarabine and idarubicin in the induction treatment of acute myeloid leukemia: Long‐term results of the p	6
Recombinant factor IX Fc for the treatment of hemophilia B	6
Treatment of Refractory Monoclonal Immunoglobulin Deposition Disease With BCMA Bispecific Antibody	6
A post hoc analysis of PROTECT VIII kids assessing long‐term efficacy and safety of damoctocog alfa pegol in adolescents with severe haemophilia A	6
Risk‐based and individualised management of bleeding and thrombotic events in adults with primary immune thrombocytopenia (ITP)	6
Clinical Management of Persistent Hypereosinophilia	6
Response rates of extra‐nodal diffuse large B cell lymphoma to anti‐CD19‐CAR T cells: A real word retrospective multicenter study	6
Featured Cover	6
Full or intensity‐reduced high‐dose melphalan and single or double autologous stem cell transplant with or without bortezomib consolidation in patients with newly diagnosed multiple myeloma	6
The role of oral iron in the treatment of adults with iron deficiency	6
Haematology Outcomes Network in Europe (HONEUR)—A collaborative, interdisciplinary platform to harness the potential of real‐world data in hematology	6
Evaluation of soluble P‐selectin as a predictive biomarker in acute symptomatic pulmonary embolism: Insights from a prospective observational study	6
Venetoclax in the Treatment of Multiple Myeloma: A Retrospective Analysis of 79 Patients	6
A prospective study of posttransplant cyclophosphamide for unrelated donor peripheral blood stem cell transplant with special attention to graft content and the impact of a higher γδ T cell dose	6
Clinical characteristics of Australian treatment‐naïve patients with classical Hodgkin lymphoma from the lymphoma and related diseases registry	6
Validation of the GATMO score in predicting non‐relapse mortality following hematopoietic cell transplant in multiple myeloma patients	6
Busulfan and cyclophosphamide‐based conditioning regimen still holds the promise of being a safe and efficacious regimen for allogeneic transplantation in patients with transfusion‐dependent thalassem	6
Issue Information	6
Pattern of use and clinical outcomes with rIX‐FP in pediatric/adolescent patients with haemophilia B in Italy: Results from IDEAL real‐world study	6
Efficacy and safety of PD‐1 monoclonal antibody plus rituximab in relapsed/refractory diffuse large B cell lymphoma patients	6
ABO Blood Type and Short‐Term Mortality in Patients With Infection‐Associated Disseminated Intravascular Coagulation	6

	6
Cyclosporine plus eltrombopag in the treatment of aplastic anemia with or without antithymocyte immunoglobulin: A multicenter real‐world retrospective study	6
Appropriateness of inpatient intravenous iron therapy in a Swiss tertiary care hospital	6
Venetoclax Combined With FLAG‐IDA in Refractory or Relapsed Acute Myeloid Leukemia	6
The Mortality of Adults With Sickle Cell Disease at a Comprehensive Sickle Cell Center	5
Outcome data from >10 000 multiple myeloma patients in the Danish and Swedish national registries	5
Patient age and donor HLA matching can stratify allogeneic hematopoietic cell transplantation patients into prognostic groups	5
Improved Outcomes of Myeloma Cast Nephropathy in Newly Diagnosed Multiple Myeloma With Modern Anti‐Myeloma Therapies	5
Unveiling the Genetic and Clinical Differences of Acute Myeloid Leukemia (AML) in Obese Patients	5
Further Reflections on 6‐MP Adherence and Habit Strength: The Impact of Dose Adjustment Complexity and Caregiver Burden	5
Assessing the Burden of C5 Inhibitor Treatment in Patients with Paroxysmal Nocturnal Hemoglobinuria	5
VEXAS syndrome: A review of bone marrow aspirate and biopsies reporting myeloid and erythroid precursor vacuolation	5
Marked hyperferritinemia in critically ill cancer patients	5
Utilization of a surgical database to provide care and assess perioperative treatment and outcomes in patients with bleeding disorders	5
CLLAF SCORE—A New Risk Score for Predicting Atrial Fibrillation in Treatment‐Naive CLL Patients Initiating First‐ and Second‐Generation BTK Inhibitor Therapy	5
The safety of Bruton's tyrosine kinase inhibitors in B‐cell malignancies: A systematic review	5
Cytogenetic and molecular characteristics and outcomes of adult patients with early T‐cell precursor acute lymphoblastic leukemia	5
Increased Non‐Relapse Mortality in Older People With Allogeneic Hematopoietic Stem Cell Transplantation Using Fludarabine and Myeloablative Dose of Busulfan‐Based Regimen	5
Treatment horizon in multiple myeloma	5
Resveratrol and tetrahydroisoquinoline effects on neutrophil sensitivity to NETosis formation in low‐risk essential thrombocythemia patients	5
Tandem bispecific CD123/CLL‐1 CAR‐T cells exhibit specific cytolytic effector functions against human acute myeloid leukaemia	5
Prognosis of patients with acute lymphoblastic leukaemia relapsing after allogeneic stem cell transplantation	5
Treatment of Critical Bleeds in Patients With Immune Thrombocytopenia: A Systematic Review	5
	5
Incidence of cardiovascular and bleeding events and reasons for discontinuation in patients with chronic lymphocytic leukemia treated with ibrutinib—A retrospective analysis on consecutive patients fr	5
Treatment Free Remission (TFR) in Chronic Phase‐Chronic Myeloid Leukemia (CP‐CML): Analysis of Predictive Factors and Novel Baseline Scoring System to Predict Molecula	5
Biological Findings and Clinical Outcomes in Patients Treated With R‐CHOP Plus High‐Dose Methotrexate as First‐Line Therapy in Large B‐Cell Lymphoma With Testis Involvement	5
Venetoclax induces deep and durable minimal residual disease‐negative remission in high‐risk TP53 disrupted B prolymphocytic leukaemia	5
Health‐related quality of life in patients with steroid‐refractory acute graft‐versus‐host disease	5
A New Strategy for Adult T‐Cell Leukemia Treatment Targeting Glycogen Synthase Kinase‐3β	5
Racial disparities in the incidence and survival outcomes in diffuse large B‐cell lymphoma in adolescents and young adults	5
Changes in body mass index during treatment of childhood acute lymphoblastic leukemia with the Nordic ALL2008 protocol	5
Comparison of telomere length in patients with bone marrow failure syndromes and healthy controls	5
Childhood autoimmune hemolytic anemia: A scoping review	5
The impact of hematology electronic consultations on the management of iron deficiency	5
Azacitidine–venetoclax versus azacitidine salvage treatment for primary induction failure or first relapsed acute myeloid leukaemia patients	5
Issue Information	5
	5
Immunophenotyping for the Assessment of Asymptomatic Lymphocytosis: A Retrospective Analysis and National Survey	5
Hyper‐CVAD and Modified CALGB‐10403 Regimens in Adult Patients With Philadelphia‐Negative Acute Lymphoblastic Leukemia: A Comparative Study	5
Clonal haematopoiesis of indeterminate potential and impaired kidney function—A Danish general population study with 11 years follow‐up	5
LP2, a stable lanthipeptide derived from cAng‐(1‐7), exerts myeloprotective action in mice	5
Real‐World Evidence of Crizanlizumab Showing Reductions in Vaso‐Occlusive Crises and Opioid Usage in Sickle Cell Disease	5
Cytokine expression in pediatric patients with immune thrombocytopenia (ITP) in different phases of disease	4
Measurable Residual Disease in UBTF‐TD Adult Acute Myeloid Leukemia	4
Venetoclax‐based non‐intensive induction followed by allogenic stem‐cell transplantation in elderly acute myeloid leukemia patients with adverse cytogenetics	4
A single‐day polychemotherapy regimen with proteasome inhibitor combinations for relapsed/refractory myeloma in the era of novel therapies	4
Upregulation of microRNA‐597 in myelodysplastic syndromes induces apoptosis through FOSL2 inhibition	4
Hydroxyurea at escalated dose versus fixed low‐dose hydroxyurea in adults with sickle cell disease	4
Reduced Intensity Conditioning Prior Autologous Stem Cell Transplantation in Elderly DLBCL Patients	4
Retrospective study on pomalidomide‐PACE as a salvage regimen in aggressive relapsed and refractory multiple myeloma	4
Autoimmune and inflammatory manifestations associated with acute myeloid leukemia with Trisomy 8—Case series and review of the literature	4
Pain and functional disability amongst adults with moderate and severe haemophilia from the Irish personalised approach to the treatment of haemophilia (iPATH) study	4
Ten‐year longitudinal analysis of hydroxyurea implementation in a pediatric sickle cell program	4
Maternal and Fetal Outcomes of Aplastic Anemia During Pregnancy and Delivery: Systematic Review and Meta‐Analysis	4
Issue Information	4
Tyrosine kinase inhibitors and tumor lysis syndrome in hematologic malignancies: A systemic review	4
Apheresis collection of mononuclear cells for chimeric‐antigen receptor therapies	4
Thromboprophylaxis for inpatient with advanced cancer receiving palliative care: A retrospective study	4
ORPHEE: A Real‐World Study on rIX‐FP Prophylaxis Use in Adolescent/Adult Patients With Hemophilia B	4
Systematic review of hematopoietic stem cell gene therapy approach in thalassemia: Comparative analysis in animal models	4
Correction to “Venetoclax‐Based Therapy for Relapsed or Refractory Acute Myeloid Leukaemia Following Intensive Induction Chemotherapy”	4
Allogeneic hematopoetic stem cell transplant for patients with refractory T‐Cell lymphomas	4
Management of infection prophylaxis in Dutch patients with myelodysplastic syndromes, a web‐based case vignette questionnaire: The MINDSET study	4
Treatment and clinical outcomes of patients with acute myeloid leukemia in Finland 2010–2020: A retrospective analysis of electronic health records	4
Identification of clinical factors impacting outcome in patients undergoing autologous hematopoietic cell transplantation after BEAM and TEAM conditioning	4
Clonal Evolution in 207 Cases of Refractory or Relapsed Acute Myeloid Leukemia	4
	4
Neutrophil to lymphocyte ratio in myelofibrosis patients treated with ruxolitinib may predict prognosis and rate of discontinuation	4
Issue Information	4
The impact of donor type on resource utilisation and costs in allogeneic haematopoietic stem cell transplantation in the Netherlands	4
Impact of secondary‐type mutations in NPM1 mutated AML	4
Issue Information	4
Chronic myeloid leukemia (CML) in children and adolescents—Clinicopathological findings	4
Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients	4
Global reported impacts of COVID‐19 on lymphoma patients and the emerging clinical management approaches in response to the ongoing pandemic	4
Molecular regulatory mechanisms of erythropoiesis and related diseases	4
Iron Deficiency in the Presence of Anemia and Inflammation—A Sex‐Specific Cross‐Sectional Study	4
Prevalence of non‐adherence and non‐compliance during maintenance therapy in adults with acute lymphoblastic leukemia and their associations with survival	4
Venetoclax‐based salvage therapy for adult patients with relapsed/refractory acute lymphoblastic leukemia	4
Herpes zoster prophylaxis with low‐dose acyclovir in patients with malignant lymphoma and multiple myeloma treated with autologous stem cell transplantation	4
Assessing Disability in Thalassaemia: A Position Statement by the Thalassaemia International Federation	4
Late transplant‐associated thrombotic microangiopathy verified in bone marrow biopsy specimens is associated with chronic GVHD and viral infections	4
Letermovir as secondary prophylaxis of cytomegalovirus infection after allogeneic hematopoietic cell transplantation: A single center experience	4
Epidemiology and clinical outcomes of light‐chain amyloidosis in Sweden: A nationwide population‐based study	4
Issue Information	4
Survival outcomes for patients with multiple myeloma in France: A retrospective cohort study using the Système National des Données de Santé national healthcare database	4
Pomalidomide, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Final Survival and Subgroup Analyses From the OPTIMISMM Trial	4
	4
Development of the Cold Agglutinin Disease Symptoms and Impact Questionnaire (CAD‐SIQ)	4
Occult ischemic bone lesions in children with sickle cell disease: A study of prevalence	4
Effects of anti‐Xa activity monitoring on the outcome of high‐risk pregnancies treated with a prophylactic dose of low‐molecular‐weight heparin	4
Prevalence of venous thromboembolism and its associations in a large racially homogenous population of sickle cell disease patients	4
	4
	4